Procalcitonin and Pneumonia: Is it a useful marker?

Current Infectious Disease Reports

Volumn 9, Issue 3, 2007, Pages 233-240

  Christ Crain, Mirjam ^a   Müller, Beat ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; PROCALCITONIN; STEROID;

ANAMNESIS; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; CULTURE TECHNIQUE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; PHYSICAL EXAMINATION; PNEUMONIA; PROGNOSIS; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 34248379523     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0037-9     Document Type: Review

References (61)

1. Becker KL, Nylen ES, White JC, et al.: Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004, 89:1512-1525.
2. Weglohner W, Struck J, Fischer-Schulz C, et al.: Isolation and characterization of serum procalcitonin from patients with sepsis. Peptides 2001, 22:2099-2103.
3. Zaidi M, Moonga BS, Abe E: Calcitonin and bone formation: a knockout full of surprises. J Clin Invest 2002, 110:1769-1771.
4. Hoff AO, Catala-Lehnen P, Thomas PM, et al.: Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002, 110:1849-1857.
5. Hirsch PF, Baruch H: Is calcitonin an important physiological substance? Endocrine 2003, 21:201-208.
6. Nylen ES, O'Neill W, Jordan MH, et al.: Serum procalcitonin as an index of inhalation injury in burns. Horm Metab Res 1992, 24:439-443.
7. Whang KT, Steinwald PM, White JC, et al.: Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998, 83:3296-3301.
8. Assicot M, Gendrel D, Carsin H, et al.: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
9. Muller B, Becker KL, Schachinger H, et al.: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983.
10. Becker KL, Muller B, Nylen ES, et al.: Calcitonin gene family of peptides. In Principles and Practice of Endocrinology and Metabolism. Edited by Becker KL. Philadelphia: Lippincott Williams & Wilkins; 2001:520-531.
11. Linscheid P, Seboek D, Nylen ES, et al.: In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003, 144:5578-5584.
12. Muller B, White JC, Nylen ES, et al.: Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001, 86:396-404.
13. Snider RH Jr, Nylen ES, Becker KL: Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997, 45:552-560.
14. Simon L, Gauvin F, Amre DK, et al.: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217.
15. Gendrel D, Bohuon C: Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000, 19:679-687; quiz 688.
16. Muller B, Peri G, Doni A, et al.: High circulating levels of the IL-1 type Il decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002, 72:643-649.
17. Galetto-Lacour A, Zamora SA, Gervaix A: Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 2003, 112:1054-1060.
18. Macfarlane JT, Colville A, Guion A, et al.: Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993, 341:511-514.
19. Chen DK, McGeer A, cle Azavedo JC, Low DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999, 341:233-239.
20. Guillemot D, Courvalin P: Better control of antibiotic resistance. Clin Infect Dis 2001, 33:542-547.
21. Ball P, Baquero F, Cars O, et al.: Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002, 49:31-40.
22. Nylen ES, Muller B, Becker KL, Snyder RH: The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 2003, 36:823-824.
23. Nylen ES, Snider RH Jr, Thompson KA, et al.: Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996, 312:12-18.
24. Muller B, Prat C: Markers of acute inflammation in assessing and managing lower respiratory tract infections: focus on procalcitonin. Clin Microbiol Infect 2006, 12(Suppl 9):8-16.
25. Christ-Crain M, Muller B: Procalcitonin in bacterial infections - hype, hope, more or less? Swiss Med Wkly 2005, 135:451-460.
26. Christ-Crain M, jaccard-Stolz D, Bingisser R, et al.: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
27. File TM Jr, Mandell LA: What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis 2003, 36:396-398.
28. Mandell LA, Bartlett JG, Dowell SF, et al.: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003, 37:1405-1433.
29. Menendez R, Torres A, Zalacain R, et al.: Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am j Respir Crit Care Med 2005, 172:757-762.
30. Wipf JE, Lipsky BA, Hirschmann JV, et al.: Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999, 159:1082-1087.
31. Harbarth S, Holeckova K, Froidevaux C, et al.: Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
32. Christ-Crain M, Stolz D, Bingisser R, et al.: Procalcitonin guidance of antibiotic therapy in co m mu nity- acquired pneumonia: a randomized trial. Am j Respir Crit Care Med 2006, 174:84-93.
33. Carratala J, Fernandez-Sabe N, Ortega L, et al.: Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005, 142:165-172.
34. Musher DM, Alexandraki I, Graviss EA, et al.: Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000, 79:210-221.
35. Arancibia F, Bauer TT, Ewig S, et al.: Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002, 162:1849-1858.
36. Genne D, Kaiser L, Kinge TN, Lew D: Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003, 9:949-954.
37. O'Donnell WJ, Kradin RL, Evins AE, Wittram C: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia. N Engl J Med 2004, 351:2741-2749.
38. Moulin F, Raymond J, Lorrot M, et al.: Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001, 84:332-336.
39. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
40. Duflo F, Debon R, Monneret G, et al.: Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002, 96:74-79.
41. Oppert M, Reinicke A, Muller C, et al.: Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation 2002, 53:167-170.
42. Gibot S, Cravoisy A: Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2004, 2:181-187.
43. Luyt CE, Guerin V, Combes A, et al.: Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005, 171:48-53.
44. Gibot S, Cravoisy A, Kolopp-Sarda MN, et al.: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma con- centrations during sepsis. Crit Care Med 2005, 33:792-796.
45. Mueller B, Gencay MM, Gibot S, et al.: Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM-1) in community-acquired pneumonia. Crit Care Med 2007, in press.
46. Gibot S, Cravoisy A, Levy B, et al.: Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004, 350:451-458.
47. Muller B: Procalcitonin and ventilator-associated pneumonia: yet another breath of fresh air. Am J Respir Crit Care Med 2005, 171:2-3.
48. Muller B, Tatum M: Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am J Respir Crit Care Med 2006, 174:848-849.
49. Fine MJ, Auble TE, Yealy DM, et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
50. Lim WS, van der Eerden MM, Laing R, et al.: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
51. Almirall J, Bolibar I, Toran P, et al.: Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
52. Masia M, Gutierrez F, Shum C, et al.: Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005, 128:2223-2229.
53. Querol-Ribelles JM, Tenias JM, Gran E, et al.: Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004, 126:1087-1092.
54. Boussekey N, Leroy 0, Alfandari S, et al.: Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006, 32:469-472.
55. Seligman R, Meisner M, Lisboa TC, et al.: Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006, 10:R125.
56. Muller B, Harbarth S, Stolz D, et al.: Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, Epub ahead of print.
57. Jensen JU, Heslet L, Jensen TH, et al.: Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596-2602.
58. Christ-Crain M, Morgenthaler NG, Stolz D, et al.: Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTNO41763971. Crit Care 2006, 10:R96.
59. Muller B, Suess E, Schuetz P, et al.: Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006, 260:568-576.
60. Mueller B, Morgenthaler NG, Stolz D, et al.: Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007, in press,
61. Villanueva JL, Cervin RJ: Serum procalcitonin levels and empirical antibiotic treatment of patients with community-acquired febrile syndromes. Clin Infect Dis 2003, 36:822. Author reply 826-827.